A high level of resilience was associated with a better mental and physical health-related quality of life among patients with multiple myeloma.
The survival advantages associated with NCCN guideline–driven care were not realized in younger patients with stage II and stage III rectal cancer.
New data support PFS as a surrogate endpoint for OS in future trials evaluating chemoimmunotherapy in DLBCL.
In the DBL3001 trial, the combination of ibrutinib and R-CHOP was not superior to treatment with R-CHOP alone.
The inverse association between circulating DBP and risk of RCC support emerging evidence for an etiologic role of DBP in cancer.
A nested case-control study found that the association between obesity and RCC varies depending on subtype.
Chemoimmunotherapy followed by lenalidomide consolidation is tolerated and extends PFS and OS in CLL patients.
A Washington University School of Medicine team’s findings might inform future research into inhibitors of angiogenesis and PD-1 in head and neck cancer.
Canadian Cancer Trials Group investigators say it's unclear if disease biology is different in younger patients or if older ones are more likely to undergo screening.
TROG 99.03 constitutes “the only high level evidence currently available to guide decision making for this group of patients,” says investigator Michael MacManus.